EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan

Bayer

Status: Completed

Conditions: Macular Degeneration

Treatments: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Study type: Observational

Funder types: Industry

Identifiers

NCT01756261

EYL-AMD-QOL (Other Identifier)

16656

Details and patient eligibility

About

The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and compared at baseline and at the 6 and 12 months after start of EYLEA treatment.

Enrollment: 757 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have been determined to start EYLEA treatment
• Patients who are registered to Special drug use investigation of EYLEA for AMD(Trial Number 15858)
• Patients who have agreed with the patient informed consent

Exclusion criteria

• Patients who have already received EYLEA

Trial design

757 participants in 1 patient group

Group 1

Treatment:

Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)